Chemed (NYSE:CHE) Updates FY24 Earnings Guidance

Chemed (NYSE:CHE) issued an update on its FY24 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $23.00-$23.15 for the period, compared to the consensus earnings per share estimate of $23.58. Chemed also updated its FY 2024 guidance to 23.000-23.150 EPS.

Chemed Trading Down 0.6 %

Shares of NYSE:CHE traded down $3.24 on Friday, reaching $537.00. The company had a trading volume of 61,625 shares, compared to its average volume of 84,553. The firm has a market capitalization of $8.08 billion, a PE ratio of 27.32, a PEG ratio of 2.18 and a beta of 0.44. Chemed has a 52-week low of $525.36 and a 52-week high of $654.62. The firm’s 50 day simple moving average is $586.09 and its 200-day simple moving average is $568.84.

Chemed (NYSE:CHE) last announced its earnings results on Tuesday, October 29th. The company reported $5.64 EPS for the quarter, missing analysts’ consensus estimates of $5.76 by ($0.12). Chemed had a return on equity of 27.86% and a net margin of 12.69%. The firm had revenue of $606.18 million during the quarter, compared to the consensus estimate of $612.22 million. During the same quarter in the prior year, the firm posted $5.32 earnings per share. The business’s revenue for the quarter was up 7.4% compared to the same quarter last year. As a group, equities research analysts predict that Chemed will post 21.77 earnings per share for the current year.

Insider Buying and Selling at Chemed

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the stock in a transaction on Monday, August 5th. The stock was sold at an average price of $569.63, for a total transaction of $1,139,260.00. Following the completion of the sale, the chief executive officer now owns 105,735 shares in the company, valued at approximately $60,229,828.05. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the company’s stock in a transaction dated Monday, August 5th. The shares were sold at an average price of $569.63, for a total transaction of $1,139,260.00. Following the transaction, the chief executive officer now owns 105,735 shares in the company, valued at $60,229,828.05. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Andrea R. Lindell sold 831 shares of Chemed stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $571.51, for a total transaction of $474,924.81. Following the completion of the sale, the director now owns 5,725 shares of the company’s stock, valued at $3,271,894.75. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 7,144 shares of company stock worth $4,141,679 over the last three months. Corporate insiders own 3.32% of the company’s stock.

Chemed Company Profile

Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers primarily in the United States. The company operates in VITAS and Roto-Rooter segments. It offers plumbing, drain cleaning, excavation, water restoration, and other related services to residential and commercial customers through company-owned branches, independent contractors, and franchisees.